Biotech Drug Report Generated Sep 13, 2026

DARE to PLAY

DARE·Dare Bioscience, Inc.

MIXED

Drug Impact Rating4/10

Trial Phase: Commercial/Compounded Product (not FDA-approved drug)
Time to Market: Already available for dispensing (Q3 2026); revenue expected to begin in the current quarter.
Why 4/10: DARE to PLAY is a compounded product, not an FDA-regulated drug, so there is no PDUFA date or pivotal readout. The next catalyst is the start of commercial dispensing and revenue generation expected in Q3 2026 (current quarter) — a commercial execution milestone rather than a hard binary event. ImpactScore is 4: the product is important for the company's survival but is not a single make-or-break binary catalyst, and the company has other pipeline programs.

Actionable Insight ◆ MIXED

Watch for Q3 2026 earnings (likely November 2026) for the first DARE to PLAY dispensing and revenue figures — this will be the first real read on commercial traction. Also monitor Nasdaq listing compliance updates and any further dilutive financing, as the company's cash runway extends only into Q4 2026.

Price Chart

Loading chart...

Executive Summary

DARE to PLAY is a branded sildenafil topical cream for female sexual dysfunction, developed by Daré Bioscience (DARE, Nasdaq). Unlike a traditional FDA-approved drug, it is a compounded prescription product that can be dispensed through pharmacies without a lengthy regulatory approval process. The company expects dispensing and initial revenue to begin in Q3 2026 (the current quarter). While the product addresses a large unmet need in women's health and analysts are overwhelmingly bullish (8 Buy/Strong Buy, 1 Hold; mean PT $8.33 vs ~$0.70 stock), Daré Bioscience is in severe financial distress — cash has burned from $24.7M to $12.6M, working capital is negative, the company faces Nasdaq delisting risk, and a dilutive S-1 registration went effective in September 2026. DARE to PLAY is one of several pipeline assets (alongside Ovaprene Phase 3 and DARE-HPV Phase 2), but the company's survival likely hinges on generating near-term product revenue.

How It Works

Sildenafil is the same active ingredient as Viagra, but formulated as a topical cream applied locally rather than a pill. It works by increasing blood flow to the genital area by relaxing blood vessels, which may help with female sexual arousal disorder. As a compounded topical cream, it is prescribed by a doctor and prepared by a compounding pharmacy, bypassing the traditional FDA drug-approval process.

Trial Status

DARE to PLAY is a compounded sildenafil cream that can be prescribed and dispensed through pharmacies without requiring FDA drug approval. The company expected dispensing and initial revenue to begin in Q3 2026. This is not a clinical-stage asset — it is a commercial product launch.

The Two-Sided Case

▲ Bull Case4

Addresses a large, underserved market — female sexual dysfunction has no widely accepted FDA-approved treatment, creating a first-mover opportunity.

Analyst consensus is overwhelmingly bullish: 8 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $8.33 (over 1,000% implied upside from the ~$0.70 stock price).

As a compounded product (not an FDA-regulated new drug), DARE to PLAY avoids lengthy clinical trials and can generate revenue quickly once dispensing begins.

The company has other pipeline value drivers: Ovaprene (Phase 3 contraceptive) and DARE-HPV (Phase 2, FDA IND cleared Feb 2026) provide additional upside optionality.

▼ Bear Case5

Severe financial distress: cash burned from $24.7M to $12.6M in H1 2026, with negative working capital and stockholders' deficit — cash runway extends only into Q4 2026.

Active Nasdaq delisting risk with a hearing scheduled in late August 2026; stock trades near its 52-week low of $0.69.

Massive dilution overhang: a ~$6M August 2026 offering at $1.37/share plus warrants for up to 200% additional shares, and an S-1 registration effective September 2026 for further potential share sales.

DARE to PLAY is a compounded product, not an FDA-approved drug — it faces competition from other compounded and over-the-counter options, and insurance reimbursement may be limited.

The company has no product revenue history; the first commercial launch (Flora Sync LF5, July 2026) is too early to judge traction.

Upcoming Catalysts

Q3 2026 earnings (est. Nov 2026): first DARE to PLAY dispensing and revenue disclosure
Nasdaq listing compliance determination (hearing held late Aug 2026)
Potential further dilutive financing given cash runway only into Q4 2026
Ovaprene Phase 3 enrollment completion (expected 2026)
DARE-HPV Phase 2 trial initiation (IND cleared Feb 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Dare Bioscience, Inc. 8-K DARE ·Originating report

Sources · 3

Hover a chip for the title

1 sec.gov2 sec.gov3 sec.gov